☰
✕
Cefpodoxime in the management of uncomplicated Gonococcal Urethritis in HIV-infected patients

Cefpo (Cefpodoxime)

Efficacy of cefpodoxime in the management of uncomplicated gonococcal urethritis in HIV-infected patients

Background:

Fluoroquinolone-resistant Neisseria gonorrhoeae is widely prevalent in the United States (US), due to which fluoroquinolones are no more recommended for the treatment of gonococcal infections. The Centers for Disease Control and Prevention (CDC) has recommended oral cefpodoxime for the management of this condition.

"Cefpodoxime was effective and well tolerated by patients with gonococcal infection"

Methods:

 

A study was conducted to demonstrate the efficacy of single 400 mg oral dose of cefpodoxime in gonococcal infections. The study included the following:

  1. Two HIV positive patients with gonococcal infection
  2. The urethral cultures of the patients were positive for C. trachomatis and N. gonorrhoeae
  3. They were randomized to receive once daily dose of 400 mg cefpodoxime.

Results:

The results revealed that after seven days of therapy with cefpodoxime the cultures were found to be negative for both the organisms.

Conclusion:

The researchers therefore concluded that cefpodoxime was effective and well tolerated by patients with gonococcal infection.

Source: Psevdos G Jr, Sharp V. Successful treatment of uncomplicated gonococcal urethritis in HIV-infected patients with single-dose oral cefpodoxime. Can J Infect Dis Med Microbiol. 2010 Fall;21(3):e109-10.